iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 115.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,225 shares of the company’s stock after buying an additional 30,619 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.16% of iTeos Therapeutics worth $439,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in iTeos Therapeutics during the 3rd quarter worth approximately $102,000. Clear Harbor Asset Management LLC purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth $96,000. SG Americas Securities LLC lifted its position in shares of iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares during the last quarter. Marquette Asset Management LLC acquired a new position in shares of iTeos Therapeutics during the fourth quarter worth $122,000. Finally, Wells Fargo & Company MN increased its holdings in iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock valued at $128,000 after buying an additional 2,402 shares during the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $7.15 on Thursday. The company has a market cap of $273.09 million, a PE ratio of -2.27 and a beta of 1.43. The stock has a fifty day moving average price of $6.59 and a 200 day moving average price of $7.65. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. Analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reissued an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. lowered their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.